Patents by Inventor Luca Mologni

Luca Mologni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2-acylaminothiazoles for the treatment of cancer
    Patent number: 9708279
    Abstract: The present invention relates to inhibitors of the oncogenic protein kinase ALK of formula (I): as herein described and pharmaceutical compositions thereof. The compounds of formula (I) are useful in the preparation of a medicament, in particular for the treatment of cancer.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: July 18, 2017
    Assignees: UNIVERSITÁ DEGLI STUDI DI MILANO—BICOCCA, UNIVERSITÈ DE GENÈVE, UNIVERSITÈ CLAUDE BERNARD LYON 1
    Inventors: Carlo Gambacorti-Passerini, Luca Mologni, Leonardo Scapozza, William Bisson, Peter Goekjian, Joseph D'Attoma
  • 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER
    Publication number: 20160257658
    Abstract: The present invention relates to inhibitors of the oncogenic protein kinase ALK of formula (I) as herein described and pharmaceutical compositions thereof. The compounds of formula (I) are useful in the preparation of a medicament, in particular for the treatment of cancer.
    Type: Application
    Filed: July 3, 2014
    Publication date: September 8, 2016
    Inventors: Carlo GAMBACORTI-PASSERINI, Luca MOLOGNI, Leonardo SCAPOZZA, William BISSON, Peter GOEKJIAN, Joseph D'ATTOMA
  • Alpha-carbolines for the treatment of cancer
    Patent number: 9428500
    Abstract: The present invention relates to inhibitors of the oncogenic protein kinase ALK of formula (I) as herein described and pharmaceutical compositions thereof, as well as to key intermediates towards their synthesis. The compounds of formula (I) are useful in the preparation of a medicament, in particular for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: August 30, 2016
    Assignees: UNIVERSITA DEGLI STUDI DI MILANO—BICOCCA, UNIVERSITE DE GENEVE, UNIVERSITE CLAUDE BERNARD—LYON
    Inventors: Carlo Gambacorti-Passerini, Luca Mologni, Leonardo Scapozza, William Bisson, Shaheen Ahmed, Peter Goekjian, Sébastien Tardy, Alexandre Orsato, David Gueyrard, Joseph Benoit
  • ALPHA-CARBOLINES FOR THE TREATMENT OF CANCER
    Publication number: 20150105554
    Abstract: The present invention relates to inhibitors of the oncogenic protein kinase ALK of formula (I) as herein described and pharmaceutical compositions thereof, as well as to key intermediates towards their synthesis. The compounds of formula (I) are useful in the preparation of a medicament, in particular for the treatment of cancer.
    Type: Application
    Filed: May 10, 2013
    Publication date: April 16, 2015
    Inventors: Carlo Gambacorti-Passerini, Luca Mologni, Leonardo Scapozza, William Bisson, Shaheen Ahmed, Peter Goekjian, Sébastien Tardy, Alexandre Orsato, David Gueyrard, Joseph Benoit
  • Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl
    Patent number: 8895744
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in the description, to their pharmaceutical compositions and use thereof for the treatment of cancer expressing oncogenic ALK protein, particularly anaplastic large cell lymphoma (ALCL), diffuse large B cell lymphoma (DLBCL), inflammatory myofibroblastic tumors (IMT) and non-small cell lung cancer (NSCLC).
    Type: Grant
    Filed: August 27, 2009
    Date of Patent: November 25, 2014
    Assignees: Universita' Degli Studi di Milano-Bicocca, Universite' de Geneve, Universite' Claude Bernard de Lyon 1
    Inventors: Carlo Gambacorti Passerini, Luca Mologni, Leonardo Scapozza, Shaheen Ahmed, Peter G. Goekjian, David Gueyrard, Florence Popowycz, Benoit Joseph, Cedric Schneider, Pierre Garcia
  • ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL
    Publication number: 20110281862
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in the description, to their pharmaceutical compositions and use thereof for the treatment of cancer expressing oncogenic ALK protein, particularly anaplastic large cell lymphoma (ALCL), diffuse large B cell lymphoma (DLBCL), inflammatory myofibroblastic tumours (IMT) and non-small cell lung cancer (NSCLC).
    Type: Application
    Filed: August 27, 2009
    Publication date: November 17, 2011
    Applicants: Universita' Degli Studi di Milano - Bicocca, Universite' Claude Bernard de Lyon 1, Universite' de Geneve
    Inventors: Carlo Gambacorti Passerini, Luca Mologni, Leonardo Scapozza, Shaheen Ahmed, Peter G. Goekjian, David Gueyrard, Florence Popowycz, Benoit Joseph, Cedric Schneider, Pierre Garcia
  • Anaplastic lymphoma kinase assay, reagents and compositions thereof
    Publication number: 20070031907
    Abstract: Disclosed are methods for detecting ALK tyrosine kinase activity and for the identification of compounds that modulate ALK activity, peptide substrates, reagents and compositions thereof.
    Type: Application
    Filed: March 4, 2004
    Publication date: February 8, 2007
    Applicant: Istituto Nazionale Per Lo Studio E La Cura Dei Tumori
    Inventors: Lorenzo Pinna, Arianna Donella-Deana, Oriano Marin, Luca Mologni, Rosalind Gunby, Carlo Gambacorti Passerini, Leonardo Scapozza